Double-blind, randomized, multi-center, placebo-controlled, comparative, phase III trial. The
study will be conducted with two treatment groups in the form of a parallel group comparison
and will serve to compare oral treatment with either 1500 mg/d norursodeoxycholic acid
capsules or placebo capsules for the treatment of Primary Sclerosing Cholangitis.